• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet Q3 beats The Street

November 1, 2018 By Fink Densford

Insulet

Insulet (NSDQ:PODD) today posted third quarter earnings that beat expectations on Wall Street and lifted its guidance for the remaining year.

The Billerica, Mass.-based company posted profits of $1.7 million, or 3¢ per share, on sales of $151.1 million for the three months ended September 30, seeing a 174.5% swing into the black while sales grew 24.1% compared with the same period during the previous year.

Earnings per share were just ahead of the 0¢ consensus on The Street, where analysts were looking for sales of $149.4 million, which the company beat.

“Our team’s ongoing commitment to operational excellence and our expanding opportunities for growth are demonstrated in our strong third quarter performance. We grew revenue 24%, achieved gross margin expansion of 700 basis points and generated both positive operating and net income for the first time in Insulet’s history. We gained traction through the quarter in our direct European operations, successfully launched the limited commercial release of our next-generation Omnipod DASH system and made great progress in both our market access initiatives and the build out of our U.S. manufacturing facility,” chair & CEO Patrick Sullivan said in a press release.

Insulet lifted its guidance for the remaining fiscal year, expecting to post sales of between $558 million and $563 million, up from previous guidance of between $547 million and $562 million.

For its fourth quarter, the company expects to post sales of between $159 million and $164 million, up from earlier guidance of between $154.5 million and $162.5 million.

“We are very pleased with our results to date in 2018 and our team continues to drive the business forward. We remain on track to achieve both positive operating income in 2018 and our 2021 revenue and gross margin targets. Looking ahead, we are confident our innovation, commercial and operational initiatives are setting a strong foundation to deliver many more years of growth and value for Insulet shareholders,” prez & COO Shacey Petrovic said in a prepared statement.

Shares in Insulet rose approximately 2.2% today, closing at $90.13.

In September, Insulet announced that its president & COO Shacey Petrovic will succeed CEO Patrick Sullivan after he retires at the end of the year.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Insulet

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS